Shares of Arcturus Therapeutics (ARCT) have gained 7.5% over the past four weeks to close the last trading session at $12.81, ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company specializing in mRNA therapeutics and vaccines, stands at a critical juncture as it navigates a rapidly ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and ...

Now three months past its conjunction with the sun in March, Saturn is currently well separated from the dawn glow. On June 1 ...

SAN DIEGO, May 12, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

The withdrawal of the U.S. from efforts to produce an mRNA vaccine against H5N1 is indeed troubling. When it infects humans, ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Sector Outperform recommendation. As of May 7, 2025, the average one ...

If you’re a night owl, this is the perfect time of year for you, as stargazing has now become a late-night delight! Catch an ...

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago. These ...

On Wednesday, Scotiabank (TSX: BNS) began coverage on Arcturus Therapeutics (NASDAQ: ARCT), assigning a Sector Outperform rating and setting a price target of $32.00.Currently trading at $11.77 ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway.